GlassScriptPhysician profile
Maureen B Conroy
NPI 1073507927
$2,348.52
in general payments reported to CMS, 2019-2025
26 companies · $44.68 in 2025
The $44.68 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $590 · 2022: $378 · 2023: $716 · 2024: $244 · 2025: $44.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.98 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $712.69 | 2019-2024 | Lo Loestrin Fe, Ubrelvy, Orilissa |
| Intuitive Surgical, INC. | $477.24 | 2020 | |
| Astellas Pharma US INC | $266.97 | 2023-2024 | Myrbetriq, Veozah |
| Exeltis, USA INC. | $105.08 | 2022-2024 | Slynd |
| Sumitomo Pharma America, INC. | $99.78 | 2023-2024 | Gemtesa, Myfembree |
| Mayne Pharma Commercial LLC | $99.51 | 2022-2024 | |
| Shield Therapeutics INC | $66.01 | 2023-2024 | Accrufer |
| Minerva Surgical, INC | $63.94 | 2019-2022 | |
| Coopersurgical, INC. | $54.58 | 2019-2023 | Paragard T 380a |
| Organon LLC | $52.94 | 2022-2024 | Nexplanon |
| Amgen INC. | $50.33 | 2022-2024 | Prolia, Evenity |
| Pfizer INC. | $44.59 | 2023 | |
| Smith+Nephew, INC. | $27.66 | 2022-2024 | Pico 7 |
| Supernus Pharmaceuticals, INC. | $22.34 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $22.34 | 2025 | Zurzuvae |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $20.45 | 2022 | |
| Hologic Sales and Service, LLC | $19.57 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.79 | 2023 | |
| Abbott Laboratories | $17.04 | 2023 | Freestyle Libre 3 |
| Vertical Pharmaceuticals, LLC | $16.85 | 2020 | |
| Mission Pharmacal Company | $16.01 | 2020 | |
| Conmed Corporation | $15.90 | 2024 | Airseal |
| Allergan, INC. | $14.75 | 2020 | |
| Covidien LP | $14.64 | 2020 | |
| Myovant Sciences INC. | $14.33 | 2022 | |
| Merck Sharp & Dohme LLC | $14.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Conroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.